首页> 外文期刊>Therapeutic advances in gastroenterology. >From historical perspectives to modern therapy: A review of current and future biological treatments for Crohn's disease
【24h】

From historical perspectives to modern therapy: A review of current and future biological treatments for Crohn's disease

机译:从历史的角度到现代疗法:克罗恩病的当前和未来生物学治疗方法综述

获取原文
获取原文并翻译 | 示例
           

摘要

Crohn's disease (CD) is a debilitating, systemic inflammatory disorder with both gastrointestinal and extraintestinal manifestations. Its existence predates modern medicine, but its precise etiology remains incompletely understood. Most authorities suggest a multifactorial pathogenesis owing to a mixture of genetic disorders, immunologic dysregulation, microbiota disequilibrium and environmental influences. Of these factors, the overactive immunologic response seen in CD appears to be the most promising target of medical therapy. Biological agents comprise a relatively new class of drugs that can induce and maintain remission in moderate to severe CD, as well as in ulcerative colitis. This review will provide an overview of CD, its history, clinical features, pathophysiology, and treatment options focusing on current and future biological agents with an emphasis on drug development, dosage and administration.
机译:克罗恩氏病(CD)是一种具有胃肠道和肠外表现的衰弱性全身性炎症性疾病。它的存在早于现代医学,但其确切的病因仍未完全理解。由于遗传疾病,免疫学失调,微生物群失衡和环境影响的综合影响,大多数权威人士提出了多因素发病机制。在这些因素中,CD中出现的过度活跃的免疫应答似乎是药物治疗的最有希望的目标。生物制剂包括一类相对较新的药物,可以诱导和维持中度至重度CD以及溃疡性结肠炎的缓解。这篇综述将概述CD,其历史,临床特征,病理生理学和治疗方案,重点是当前和未来的生物制剂,重点是药物的开发,剂量和给药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号